Key Points
- COO Margaret Horn sold 4,967 Revolution Medicines shares at an average price of $199.24, generating approximately $989,625. The sale covered tax withholding obligations tied to vested equity awards, and she retained 149,680 shares.
- Revolution Medicines recently reported a quarterly EPS loss of $3.06, missing the consensus estimate of a $2.04 loss. Analysts nevertheless maintain a “Moderate Buy” consensus rating with an average price target of $226.17.
- Institutional investors own approximately 94.34% of RVMD, while the stock trades near $190.95 and has ranged from $42.18 to $224.31 over the past year.
Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Alan Sandler sold 341 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $67,940.84. Following the completion of the sale, the insider directly owned 52,868 shares of the company's stock, valued at approximately $10,533,420.32. The trade was a 0.64% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Revolution Medicines Trading Down 3.0%
NASDAQ:RVMD opened at $190.95 on Friday. The company has a market capitalization of $40.93 billion, a P/E ratio of -21.65 and a beta of 1.40. The stock's 50 day moving average price is $199.57 and its 200 day moving average price is $159.57. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. Revolution Medicines, Inc. has a 52 week low of $42.18 and a 52 week high of $224.31.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the business posted ($1.31) EPS. On average, research analysts forecast that Revolution Medicines, Inc. will post -8.87 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Contravisory Investment Management Inc. bought a new stake in Revolution Medicines during the second quarter valued at about $32,000. Johnson Financial Group Inc. bought a new position in shares of Revolution Medicines in the second quarter worth about $37,000. Silvant Capital Management LLC acquired a new position in shares of Revolution Medicines during the 2nd quarter worth about $41,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Revolution Medicines during the 2nd quarter worth about $41,000. Finally, Allworth Financial LP boosted its stake in Revolution Medicines by 57.2% during the 4th quarter. Allworth Financial LP now owns 577 shares of the company's stock valued at $46,000 after purchasing an additional 210 shares during the period. Institutional investors and hedge funds own 94.34% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. Guggenheim increased their target price on shares of Revolution Medicines from $240.00 to $275.00 and gave the stock a "buy" rating in a research report on Friday, August 28th. HC Wainwright upped their price target on Revolution Medicines from $195.00 to $280.00 and gave the stock a "buy" rating in a research note on Thursday, August 27th. Morgan Stanley began coverage on Revolution Medicines in a report on Thursday, September 10th. They set an "overweight" rating and a $255.00 price objective on the stock. Oppenheimer boosted their target price on Revolution Medicines from $230.00 to $260.00 and gave the stock an "outperform" rating in a report on Thursday, August 27th. Finally, Royal Bank Of Canada boosted their target price on Revolution Medicines from $203.00 to $251.00 and gave the stock an "outperform" rating in a report on Thursday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $226.17.
Get Our Latest Report on Revolution Medicines
Trending Headlines about Revolution Medicines
Here are the key news stories impacting Revolution Medicines this week:
- Positive Sentiment: Revolution Medicines recently received regulatory approval for a new medicine, validating its approach to treating certain cancers. The treatment could potentially become the most-prescribed therapy in its indication, improving the company’s long-term commercial outlook. Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
- Neutral Sentiment: A comparison article weighing Axsome Therapeutics against Revolution Medicines highlights RVMD as a healthcare investment candidate, but does not provide a clearly new company-specific catalyst. Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
- Negative Sentiment: Five company insiders, including the CFO and COO, collectively sold approximately $5.8 million of RVMD shares at $199.24 apiece. The filings state that the transactions were made to cover tax withholding obligations tied to vested equity awards, rather than for discretionary reasons. Nevertheless, the cluster of sales can create short-term supply and sentiment pressure. The insiders continued to hold substantial positions after the transactions. Revolution Medicines insider transaction filing
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.
Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
